YUHSpace

BROWSE

YUHSpace

Browsing by Yonsei Author : Sohn, Joo Hyuk

eperson profile image
Name :
Sohn, Joo Hyuk [손주혁]
orcid http://orcid.org/0000-0002-2303-2764
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (15045889800)
Medical Student Research Advisor

교수 기본정보

세부 전공
종양내과
이메일
oncosohn@yuhs.ac

실험실 기본정보

이름
유방암중개연구센터
위치
ABMRC 614호
구분
Wet Lab (100%), Dry Lab ( %)

연구소개

연구 분야
연구 내용
유방암의 중개연구 및 암환자 혈액내 DNA를 시퀀싱해서 얻은 전장유전체의 분석 연구

학생 참여 정보

학생들이 참여하면 좋을 연구
  • 연구에 대해 지도하면서 학생의 관심 분야를 의논한 후 결정하도록 하겠습니다.
학생 참여 시 사용하게 되는 장비 및 프로그램
  • 참여 결정되면 결정될 것입니다.

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 183

This table browses all dspace content
Issue DateTitleJournal Title
2025Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
2024Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial NATURE MEDICINE
2024Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study JOURNAL OF CLINICAL ONCOLOGY
2024Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2024A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer FUTURE ONCOLOGY
2024Reply to A. Okeya et alJOURNAL OF CLINICAL ONCOLOGY
2024Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study ESMO OPEN
2024Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialLANCET ONCOLOGY
2024Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study BREAST CANCER
2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3 ANNALS OF ONCOLOGY
2024A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer NPJ BREAST CANCER
2024Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer CANCER IMMUNOLOGY IMMUNOTHERAPY
2024Reversion of pathogenic BRCA1 L1780P mutation confers resistance to PARP and ATM inhibitor in breast cancer ISCIENCE
2024Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2-metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.JOURNAL OF CLINICAL ONCOLOGY
2024A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trialJOURNAL OF CLINICAL ONCOLOGY
2024Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study JOURNAL OF CLINICAL ONCOLOGY
2024IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy CELL REPORTS MEDICINE
2024Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY BREAST CANCER RESEARCH AND TREATMENT
2024Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation EXPERIMENTAL AND MOLECULAR MEDICINE
2024Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) ANNALS OF ONCOLOGY
2024TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerFUTURE ONCOLOGY
2024Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer CLINICAL CANCER RESEARCH
2024A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2024Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trialEUROPEAN JOURNAL OF CANCER
2023Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16) EUROPEAN JOURNAL OF CANCER
2023Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
2023A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy CANCER RESEARCH AND TREATMENT
2023Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer CANCER RESEARCH AND TREATMENT
2023Machine Learning Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy for ER+HER2- Breast Cancer: Integrating Tumoral and Peritumoral MRI Radiomic Features DIAGNOSTICS
2023Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2023Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer ESMO OPEN
2023Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.JOURNAL OF CLINICAL ONCOLOGY
2023Capivasertib in Hormone Receptor-Positive Advanced Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2023A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) CANCER RESEARCH AND TREATMENT
2023Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA NATURE COMMUNICATIONS
2023Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerEUROPEAN JOURNAL OF CANCER
2023Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2 CANCER SCIENCE
2023Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) CANCER RESEARCH AND TREATMENT
2023Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerJOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
2023On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates BREAST CANCER RESEARCH
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2023Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP CANCER MEDICINE
2022Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)BREAST
2022Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialJOURNAL OF CLINICAL ONCOLOGY
2022Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial JAMA ONCOLOGY
2022Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
2022Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2022Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer CANCERS
2022Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantCLINICAL CANCER RESEARCH
2022Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial ANNALS OF ONCOLOGY
1234
  • License
    sherpa_romeo
    sherpa_juliet

OAK

DSpace Software Copyright © 2002-2017 Duraspace Yonsei University Medical Library All right Reserves. / TEL:02-2228-2915 /
YUHSpace는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.

Browse

Links